339209-12-0

Upstream product

• 536-25-4 methyl 3-amino-4-hydroxybenzoate 
• 207235-85-6 2-[5-benzyloxycarbonylamino-2-(4-fluorophenyl)-6-oxo-1,6-dihydro-1-pyrimidinyl]-N-[1-[(5-carboxylbenzoxazol-2-yl)hydroxymethyl]-2-phenylethyl]acetamide 
• 207235-80-1 2-[5-benzyloxycarbonylamino-2-(4-fluorophenyl)-6-oxo-1,6-dihydro-1-pyrimidinyl]-N-[1-[[5-(methoxycarbonyl)benzoxazol-2-yl]hydroxymethyl]-2-phenylethyl]acetamide 
• 207235-69-6 2-benzyloxycarbonylamino-1-hydroxy-1-[5-(methoxycarbonyl)benzoxazol-2-yl]-3-phenylpropane 
• 207235-68-5 2-amino-1-hydroxy-1-[5-(methoxy-carbonyl)benzoxazol-2-yl]-3-phenylpropane 
• 66413-45-4 3-(benzyloxycarbonyl)amino-2-hydroxy-4-phenylbutanenitrile 
• 59830-60-3 N-benzyloxycarbonyl-2-amino-3-phenylpropionaldehyde 

Relevant academic research and scientific papers

Synthesis, structure - Activity relationships, and pharmacokinetic profiles of nonpeptidic α-keto heterocycles as novel inhibitors of human chymase

We designed nonpeptidic chymase inhibitors based on the structure of a peptidic compound (1) and demonstrated that the combination of a pyrimidinone skeleton as a P3-P2 scaffold and heterocycles as P1 carbonyl-activating g